ClinicalHeart FailureSex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms
Graphical abstract
Keywords
Cited by (0)
Funding Sources: This work was supported by a grant from the Leducq Foundation [Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN)]; by grants from the Netherlands Heart Foundation (CVON PREDICT2 Grant 2018-30); by other grants (CVON-eDETECT Grant 2015-12, CVON SHE-PREDICTS-HF Grant 2017-21, CVON RED-CVD Grant 2017-11, CVON DOUBLE DOSE Grant 2020B005); and by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF).
Disclosures: The UMCG, which employs several of the authors, received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. Dr de Boer received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Dr Wilde is a member of the steering committee of LQT Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.